Graves disease

M.Hashemipour Pediatric Endocrinologist

Isfahan University of Medical Sciences
Endocrine &metabolic research center
Child growth &development research center



Content

- Definition
- Predisposing factors
- Associated disorders
- Clinical manifestation
- Pathogenesis
- Diagnosis
- When and How to Treat
- Monitoring of children taking MMI
- How long ATDs should be used in children

Definition

- Hyperthyroidism
- An inappropriately high synthesis and secretion of thyroid hormone by the thyroid
- Thyrotoxicosis
- Clinical manifestations of inappropriately high thyroid hormone action in tissues.

Graves' disease

- Accounts for \ \ \ \ \ \ \ \ \ \ \ \ \ \ of all childhood thyroid abnormalities
- Its incidence peaks between age 11 and 12 years
- Predominantly affecting females

Graves Disease

- About **% of GD patients have family members who also have GD or Hashimoto's thyroiditis.
- Twin studies have shown that ^ % of the susceptibility to GD is genetic
- Monozygot twins have higer incidence than dizygot twins

Associated disorders

is associated with

- Type \ diabetes
- Celiac disease
- Addison disease
- systemic lupus erythematosus
- Hashimoto thyroiditis
- pernicious anemia
- Down syndrome
- Turner syndrome

Associated disorders

- is associated with
- Hepatitis c
- Congenital rubella
- Y.entrocolitis
- Helicobacter
- Retroviral

Clinical manifestation

- Fatigue
- Excessive sweating
- irritability
- Nervousness
- Emotional lability
- poor concentration
- Sleep disturbance



Diagnosis is easily overlooked in teenage girls with weight loss who are assumed to have an eating disorder

Cardiac manifestation

Childhood

- Blood pressure, tachycardia, precordial thrill, and an ejection murmur due to functional insufficiency of the mitral valve
- wide pulse pressure
- Palpitations

Neuromuscular disease

- Hyperactive DTR
- Fine tremor

Neuromuscular disease

- Hypokalemic periodic paralysis
- May be associated with myasthenia gravis and thymic enlargement

Bone disease

- osteoporosis
- Restoration to normal for two years on ATD treatment

Ophtalmologic manifestation


- Children present milder ophthalmic abnormalities than adults, mostly
- staring eyes
- soft tissue involvement
- Retraction of the upper lid
- wide palpebral aperture
- Exophthalmos (proptosis)





Ophtalmologic manifestation

 Diffuse goiter symmetric, firm and uniformly smooth, without tenderness





Gastrointestinal involvment

• The prevalence of celiac disease and IBD is probably modestly increased

Clinical manifestation

- Reduction in menstrual flow or oligo-menorrhea
- urinary frequency
- Gynecomastia
- Weight loss despite increased apptite

Clinical manifestation

- Increased perspiration
- Heat intolerance
- Warm, moist and smooth skin
- palmar erythema
- Thin and fine hair
- Vitiligo and alopecia areata
- softening of the nails



Pathogenesis

- is autoimmune disease whose major manifestations are owing to circulating Ab that stimulate TSH-R
- . TSH stimulating Ab leading to the release of TH and thyrocyte growth.

Diagnosis

Serology

- Serum TSH has the highest sensitivity and specificity for assessing TH excess.
- should be used as an initial screening test
- Accuracy improves when TSH and free T[¢] are assessed at the time of the initial evaluation.

TSH Receptor Antibody

- TSH-R-Ab are specific biomarkers for diagnosis of GD.
 - 90 % of clinical GD will have positive TRAB

TSH Receptor Antibody

- TRAb is a sensitive and specific tool for rapid and accurate diagnosis and differential diagnosis of Graves' hyperthyroidism.
- for prognostic purposes
- for monitoring ATD therapy
- for timing of stopping therapy
- Allows long term ATD therapy in some cases
- > Execellent predictive value for relaps

Thyroid Peroxidase Antibody

- TPOab
- The most sensitive serologic test for detecting autoimmune thyroid disease

Imaging

- Thyroid US is a convenient, noninvasive, rapid, and accurate tool in the initial work-up of GD patients
- It aids in the diagnosis, without exposing the patient to ionizing irradiation, and assists in determining the underlying etiology of thyrotoxicosis and detecting concomitant thyroid nodules that may change management

Imaging

 characterized by diffuse thyroid enlargement and by normal echo or hypoechogenicity, both assessed by US and conventional grey scale analysis

Imaging

• A color-flow Doppler shows vascular patterns and quantifies thyroid vascularity.

Thyroid scintigraphy

- Typical US patterns combined with positive TSH-R-Ab obviate the need for scintigraphy in the vast majority of cases.
- There is no indication for CT scan, MRI, or PET-CT of the thyroid gland

When and How to Treat

How to Choose Treatment?

- What are treatment choices?
- How to select treatment?

Key Points before Treatment

- Discuss with pt logistics, benefits, speed of recovery, drawbacks, potential side effects and cost
- Final decision on choice of treatment depends on resources pt preference and physician experience

Key Points before Treatment

 Patients should refrain from sporting activities until thyroid function normalizes.

After this normalization, no particular restrictions are needed except for participating in vigorous sporting activities.

Key Points before Treatment

- Check WBC & liver profile before treatment
- Routine recheck not necessary

Choice of treatment

- *Safety
- *Efficacy
 - **□**Improvement
 - **□**Cure

Management

Graves' hyperthyroidism is treated by reducing

- TH synthesis by using antithyroid drug (ATD)
- The destruction of thyroid tissue with RAI or total thyroidectomy

Medical Treatment

Thionamides

inhibit the function of thyroperoxidase Reduce TSH-RAb and enhance rates of remission compared to no therapy.

Table 1. Mechanism of action of antithyroid drugs

Intrathyroidal inhibition of:

Iodine oxidation/organification

Iodotyrosine coupling

Thyroglobulin biosynthesis

Follicular cell growth

Extrathyroidal inhibition of T4/T3 conversion (PTU)

Methimazole

- Methimazole is preferred because of
- ▶ its longer duration of action allowing for once daily dosing
- More rapid efficacy
- lower incidence of side effects
- ➤ The half-life in plasma of methimazole is about fours, whereas that of propylthiouracil is about hours

Monitoring of children taking MMI

■ Measure FT[¢] and T^r every [¢] to [¢] weeks initially.

• Repeated test in $^{\varphi}$ - $^{\varphi}$ weeks until thyroid function is normal.

After thyroid function has normalized

Repeat free T^{\(\tau\)}, T^{\(\tau\)}, and TSH at \(\tau-\) month intervals

Clinical response

- Normalizing thyroid hormone within six weeks
- Clinical response becomes apparent in ^r−^r wk
- Adequate control is evident in *-* mo
- Tr levels are important to monitor initially

Clinical response

- TSH generally becomes detectable in the serum after two to four months
- Patients with persistently low serum TSH after more than six months of therapy are unlikely to have a remission
- consider drug discontinuation

Beta-Adrenergic Blockade

- Propranolol
- Atenolol/bisoprolol, β \(\) selective , are useful to control adrenergic symptoms such as palpitations and tremor

Criteria for Antithyroid Drug Discontinuation

- if normal thyroid function is maintained with the maintenance dose of an antithyroid drug approximately △ mg of MMI/every other day to △ mg/d for more than ⁹ mo
- Consider discontinuation of the drug.

Criteria for Antithyroid Drug Discontinuation

• If the goiter decreases in size and negative TRAb results are maintained, the patient may have achieved remission

How long ATDs should be used in children?

long-term treatment for up to \' years
we prescribe MMI indefinitely till
leaving home for college

The comparisn between three modalities

	Advantage	Hypothyroidis m	Disadvantage	Cost
ATD	Nonablative	Low	Recurrence side effects	+
RAI	Definitive	1%	Fear	++
Surgery	Definitive	1%	Complications	+++

Conclusion

Diagnosis of graves is based on

- Clinical manifestation
- TSH Rab
- Throid function Test
- Sonography

Criteria for Antithyroid Drug Discontinuation

- TSH Rab
 - Size of thyoid
 - Dose of Methimazole
 - Concentration of thyroid hormone

